Clinical Trial Update: Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial comparing NN5401 to Biphasic Insulin Aspart 30 on a twice-daily regimen in adults with Type 2 diabetes; results completed and posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)
• NN5401

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20